Key Highlights

  • Q3 2026 Royalty Revenue rose 51% year-over-year to $70.3 million, representing 89% of total revenues
  • Adjusted Net Income of $57.5 million, or $2.67 per diluted share, for the quarter
  • Company raises full-year 2026 adjusted diluted EPS guidance to $9.50–$9.75, from prior range of $9.00–$9.50
  • Cash, equivalents, and short-term investments of $447.4 million as of September 30, 2026

Royalty Business Delivers Standout Quarter

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted third quarter 2026 royalty revenue of $70.3 million, a 51% increase from $46.6 million reported in the same period of 2025. The jump was driven by newly acquired XOMA portfolio Assets alongside continued commercial traction from key royalty partners, including Travere Therapeutics' Filspari and Merck's Ohtuvayre. Royalty revenue accounted for 89% of total revenues during the quarter.

Total revenues and income for Q3 2026 were $78.7 million, compared with $115.5 million in the prior-year period. However, the prior year included $53.1 million in Pelthos divestiture-related income. Excluding that one-time benefit, total revenues rose 26% year-over-year. Captisol sales were $7.9 million, reflecting normal timing of customer orders, while contract revenue came in at $0.5 million.

Profitability and Expense Trends

Adjusted net income for Q3 2026 was $57.5 million, or $2.67 per diluted share, compared to $63.8 million, or $3.09 per diluted share, in the prior year. The decline was largely attributable to $24.5 million of Pelthos out-license income recognized in the prior period and higher general and administrative expenses, offset by the substantial royalty revenue growth.

General and administrative expenses rose to $72.6 million from $28.4 million in the prior year. This increase primarily reflected transaction and integration costs related to the XOMA acquisition, higher share-based compensation, and expanded headcount to support Ligand's growing royalty Portfolio Management platform. Amortization of Intangibles increased to $10.2 million from $8.1 million, also tied to the XOMA acquisition.

GAAP net loss for the quarter was $28.5 million, or $1.43 per share, versus net income of $117.3 million in the prior-year period. The Q3 2026 GAAP result included $39.5 million in pre-tax losses from changes in Fair Value of equity-method and other investments, as well as short-term Investment losses.

Year-to-Date Performance and Balance Sheet

For the nine months ended September 30, 2026, royalty revenue grew 46% to $161.3 million compared to $110.5 million in the prior-year period. Total revenues were $194.2 million versus $208.4 million, with the prior year again benefiting from significant Pelthos-related income. Excluding that, total revenues increased 25% year-over-year.

Adjusted net income for the nine-month period was $142.9 million, or $6.67 per diluted share, up from $122.4 million, or $6.07 per diluted share. The improvement was fueled by higher royalty revenue, increased net interest income, and realized gains on short-term investments, partially offset by elevated G&A costs.

As of September 30, 2026, Ligand held cash, cash equivalents, and short-term investments of $447.4 million, down from $733.5 million at year-end 2025 due to cash deployed in the XOMA acquisition, offset by proceeds from its convertible senior notes due 2031. Including Equity investments and revolving Credit availability, the company has approximately $750 million of deployable Capital for future royalty acquisitions and investments.

Guidance Raised; Strategic Highlights

Ligand raised its full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75, up from the prior range of $9.00 to $9.50, reflecting confidence in royalty momentum. Full-year revenue guidance was reaffirmed, with royalty revenue expected at $225 million to $250 million, Captisol sales of $35 million to $40 million, contract revenue of $10 million to $20 million, and total revenue of $270 million to $310 million.

During the quarter, Ligand continued its royalty Acquisition strategy by entering into a royalty interest in Santen's Ryjunea and a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline. The company is scheduled to host an investor day on December 8, where it will share an updated five-year financial outlook. CEO Todd Davis noted the company is well positioned to continue executing its royalty aggregation strategy.

Ligand Pharmaceuticals delivered a quarter defined by accelerating royalty momentum, with the XOMA portfolio assets increasingly contributing to revenue diversification. The company's strategy of aggregating royalty interests across a portfolio of over 200 assets appears to be bearing results, and an updated multi-year outlook expected at its December investor day could offer further clarity on its growth trajectory.

What drove Ligand's royalty revenue growth in Q3 2026?

Royalty revenue growth was primarily driven by contributions from the newly acquired XOMA portfolio assets, as well as continued commercial momentum from Travere Therapeutics' Filspari and Merck's Ohtuvayre.

How did Ligand's GAAP Earnings differ from adjusted earnings in Q3 2026?

GAAP net loss was $28.5 million due to $39.5 million in pre-tax non-cash losses from fair value adjustments on investments. Adjusted net income, which excludes these items, was $57.5 million, or $2.67 per diluted share.

What is Ligand's updated full-year 2026 earnings guidance?

Ligand raised its adjusted diluted EPS guidance to $9.50–$9.75 for full-year 2026, up from the prior range of $9.00–$9.50. Revenue guidance was reaffirmed, with total revenues expected between $270 million and $310 million.

How much deployable capital does Ligand have for future acquisitions?

As of September 30, 2026, Ligand had approximately $750 million of deployable capital, including cash and equivalents of $447.4 million, equity investments, and revolving credit Facility availability.